| Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML) |
|
Leukemia |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
|
Haematologica |
Aplastic Anemia |
| Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantat |
|
Journal for immunotherapy of cancer |
Myelodysplastic Syndromes (MDS) |
| PNH Phenotypes and Their Genesis |
|
British Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| PNH and complement gene variants |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia |
|
Immunotherapy |
Aplastic Anemia |
| Pitfalls in Assessing Response to Treatment in MDS |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
